An uncontrolled open-label, multicenter study to monitor the antiviral activity and safety of inhaled zanamivir (as rotadisk via diskhaler device) among chinese adolescents and adults with influenza-like illness

Chinese Medical Journal

Volumn 125, Issue 17, 2012, Pages 3002-3007

  Cao, Bin ^a   Wang, Da yan ^b   Yu, Xiao min ^a   Wei, Lu qing ^c   Pu, Zeng hui ^d   Gao, Yan ^e   Wang, Jing ^f   Dong, Jian ping ^g   Li, Xiao ling ^h   Xu, Qian ⁱ   Hu, Ke ^j   Chen, Bai yi ^k   Yu, Yun song ^l   Song, Shu fan ^a   Shu Dr , Yue long ^b   Wang Dr , Chen ^a,m  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b National Institute for Viral Disease Control and Prevention   (China)

^c MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^d YANTAI YUHUANGDING HOSPITAL   (China)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g Beiing Hai Dian Hospital   (China)

^h Chengdu Infectious Disease Hospital   (China)

ⁱ CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^j RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^k CHINA MEDICAL UNIVERSITY   (China)

^l ZHEJIANG UNIVERSITY   (China)

^m BEIJING HOSPITAL   (China)

more..

Author keywords

Influenza; Safety; Susceptibility; Zanamivir

Indexed keywords

PARACETAMOL; VIRUS RNA; VIRUS SIALIDASE; ZANAMIVIR;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BRONCHOSPASM; CHILD; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTRANSAMINASEMIA; IC 50; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS A H1N1; INHALER; LEUKOCYTOSIS; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MONOCYTOSIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; NOSE DISEASE; OPEN STUDY; RASH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SINUS BRADYCARDIA; THROMBOCYTOPENIA; VIRUS CULTURE; VIRUS ISOLATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; ZANAMIVIR;

EID: 84866068259     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.17.007     Document Type: Article

References (17)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25: 5086-5096.
2. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The under recognized burden of influenza in young children. N Engl J Med 2006; 355: 31-40.
3. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-261.
4. Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infection 2000; 40: 42-48.
5. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 2000; 181: 1471-1474.
6. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neutrominidase inhibitor zanamivir in the treatment of influenza virus infections. New Engl J Med 1997; 337: 874-880.
7. Zhou J, Zou L, Zhang X, Liao J, Ni H, Hou N, et al. Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009. J Clin Microbiol 2011; 49: 2651-2655.
8. Leung TW, Tai AL, Cheng PK, Kong MS, Lim W. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. Journal of Clinical Virology 2009; 46: 298-299.
9. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.
10. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363-1373.
11. Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000; 44: 78-87.
12. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-1881.
13. Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug Saf 1999; 21: 267-281.
14. Gravenstein S, Johnston SL, Loeschel E, Webster A. Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Drug Saf 2001; 24: 1113-1125.
15. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med 2000; 342: 661-662.
16. Cass LM, Gunawardena KA, Macmahon MM, Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med 2000; 94: 166-173.
17. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virology 2009; 83: 10366-10373.